Planttech Carob Concentrate Improves Insulin Sensitivity in Participants with Elevated Glucose

Why It Matters

The findings suggest a natural, well‑tolerated ingredient could delay progression from prediabetes to type 2 diabetes, offering food‑industry players a clinically backed solution for glucose‑management products.

Key Takeaways

• 6.66 g daily carob extract lowered HbA1c in prediabetics.
• Insulin resistance indices improved only in active group.
• No adverse effects reported during 90‑day trial.
• Study limited by single center and 52 participants.

Pulse Analysis

Prediabetes affects roughly 1 in 3 adults in the United States, representing a massive unmet need for interventions that can be integrated into everyday nutrition. While pharmaceuticals dominate the treatment landscape, consumers increasingly demand plant‑based, evidence‑backed ingredients that align with the growing wearables market tracking glucose spikes in real time. Carob (Ceratonia siliqua), long used in Mediterranean diets, contains a suite of inositols and polyphenols that have attracted scientific interest for their insulin‑mimetic properties. Planttech’s LVLD liquid concentrate taps into this heritage, positioning itself as a functional‑food component rather than a drug.

The recent double‑blind, placebo‑controlled trial conducted by UCAM and the Biomedical Research Institute of Murcia provides the first human data confirming the metabolic benefits of a standardized carob extract. Over 90 days, participants consuming 6.66 g of the LVLD syrup each day experienced statistically significant reductions in HbA1c, fasting glucose, and insulin resistance indices compared with the placebo group. Mechanistically, the blend of D‑pinitol, myo‑inositol, D‑chiro‑inositol, and ancillary polyphenols appears to create an “entourage effect” that both dampens intestinal glucose absorption and enhances peripheral insulin signaling. Importantly, the product was well tolerated, with zero adverse events recorded.

From a commercial perspective, these results open a pathway for ingredient manufacturers and supplement brands to market a clinically validated, natural glucose‑management solution. The data align with the broader trend of functional beverages and fortified foods targeting metabolic health, a segment projected to exceed $30 billion globally by 2028. Planttech’s plan to scale the clinical program with larger, multi‑center studies will be crucial for regulatory acceptance and for convincing large‑scale food processors to adopt the extract. If subsequent trials replicate the initial efficacy, the carob concentrate could become a cornerstone of preventive nutrition strategies aimed at curbing the rise of type 2 diabetes.